CME Bridge List
Visualizing Updates in Melanoma Management: Novel Combinations, Development, and Best Practices in Sequencing Therapy
This educational virtual pathways program will help healthcare providers to optimize immunopathological assessment of melanoma, particularly in consideration of patterns of resistance. Specifically, the programming will improve clinicians’ knowledge of the latest data on combination therapies in advanced melanoma across settings of care, while preparing them to manage adverse events with these combination therapies for advanced melanoma.
RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024
Key Developments in the Management of Melanoma: Current Combinations, Therapies in Development, and Sequencing Considerations
This educational enduring program will help healthcare professionals to optimize patient outcomes for those with advanced melanoma without actionable melanoma mutations. Specifically, the programming will improve clinicians’ knowledge of the latest data concerning appropriate assessment of melanoma from a clinical pathologic view and familiarize them with current updates with single-agent and combination therapy in advanced melanoma across settings of care, while preparing them to best manage adverse events across these therapies.
RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024
An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies
This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician's assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immunotherapy approaches in advanced melanoma.
RELEASED DATE: March 03, 2023
EXPIRATION DATE: March 03, 2024